CSI Market
Sign In | Register

Generex Biotechnology (GNBT) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access GNBT Annual Cash Flow →
By examining cash flow figures across successive periods, users can identify shifts in Generex Biotechnology's cash generation and deployment strategy.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Apr 30 2021)
9 Months 		(Jan 31 2021) (Oct 31 2020) (Jul 31 2020) (Apr 30 2020)
Operating Activities
Income-26.91
Depreciation & amortization0.78
Amortization of Other Assets1.03
Increase (Decrease) in Deferred Revenue0.00
Other Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.51
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property0.01
Share-based Compensation2.17
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Reduction Of Notes Receivable Common Stock Exchange For Services Rendered-
Write Off Of Uncollectible Notes Receivable Common Stock-
Write Off Of Deferred Debt Issuance Cost-
Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost-
Amortization Of Options And Option Modifications As Employee Compensation-
Common Stock Issued For Services Rendered-
Amortization Of Prepaid Services In Conjunction With Common Stock Issuance-
Issuance Of Warrants Additional Exercise Right Inducement-
Preferred Stock Issued For Services Rendered-
Treasury Stock Redeemed For Non Performance Of Services-
Amortization Of Deferred Debt Issuance Costs Loan Origination Fees-
Founders Shares Transferred For Services Rendered-
Fees In Connection With Refinancing Of Debt-
Stock Issued During Period Value Issued For Services-
Common Stock Issued For Makewhole Payments On Preferred Stock-
Goodwill And Intangible Asset Impairment-
Noncash Interest Expense From Issuance On Debt Derivative-
Change In Fair Value Of Derivative Liabilities Convertible Notes-0.43
Change In Fair Value Of Common Stock Payable-0.10
Increase Decrease In Contract With Customer Liability7.00
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.11
Accounts Payable17.73
Increase (Decrease) in Interest Payable, Net0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Intangible Assets, Current0.00
Other Working Capital-0.23
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-3.41
Discontinued operations0.00
Net Cash flow from Operating Activities-1.74
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Cash Received In Acquisition Of Business-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net2.05
Other borrowing transactions0.00
Long-term debt - borrowings-0.02
Long-term debt - repayments-2.35
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock3.71
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Change In Notes Receivable Common Stock-
Payment Of Costs Associated With Convertible Debentures-
Proceeds From Convertible Note Payable-
Repayment Of Convertible Note Payable-
Investment In Subsidiary By Noncontrolling Interest-
Antigen Dividen-
Conversion Of Hds Debt And Issuance Of Call Option-
Conversion Of Debts To Equity-
Exercise Of Call Option-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities3.40
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-1.74
Total Cash Flow1.66
4 historic quarters locked

Sign in to unlock the full Generex Biotechnology cash flow history.

Sign In Create Free Account

About GNBT Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.